Physician profile
Molly Anne Asper
NPI 1992422711
$1,935.34
in general payments reported to CMS, 2019-2025
16 companies · $23.22 in 2025
The $23.22 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.51 · 2023: $1,737 · 2024: $157 · 2025: $23.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.10 | 2022-2024 | |
| Celgene Corporation | $317.43 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.78 | 2023 | Xifaxan, Trulance |
| Qol Medical, LLC | $138.12 | 2023 | Sucraid |
| Ardelyx, INC. | $115.40 | 2023 | Ibsrela |
| Genzyme Corporation | $97.97 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $94.55 | 2023-2024 | Rebyota |
| Gilead Sciences, INC. | $72.27 | 2023 | |
| Pfizer INC. | $70.91 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.11 | 2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $50.05 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $49.75 | 2023-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $46.26 | 2023 | Dificid |
| Janssen Biotech, INC. | $27.80 | 2023 | Simponi, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $18.59 | 2024 | Voquezna |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $16.25 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Asper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.